Phacetoperane for treating of attention deficit hyperactivity disorder

Abstract

The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane.

1 - 10 . (canceled) 
     
     
         11 . A pharmaceutical composition comprising a therapeutically effective amount of levophacetoperane, or a pharmaceutically acceptable salt thereof, for the treatment of attention deficit hyperactivity disorder (ADHD) and a pharmaceutical acceptable excipient. 
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein the therapeutically effective amount for the treatment of ADHD ranges from about 5 mg to about 20 mg. 
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein the therapeutically effective amount for the treatment of ADHD ranges from about 5 mg to about 10 mg. 
     
     
         14 . A tablet comprising the pharmaceutical composition of  claim 11 .